PROCEPT BioRobotics Corp PRCT
1 trading plan running, 13 Form 144 notices for $717K
10-Q, 10-K and Form 144What PRCT's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From Feb 29, 2024 to Jun 17, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.
| Insider | What | Date | Reported in | ||
|---|---|---|---|---|---|
| Kevin Waters Chief Financial Officer |
Adopted 10b5-1 plan | Mar 18, 2026 | 10-Q Apr 30, 2026 | ||
What the company wroteOn March 18, 2026, Kevin Waters, the Company’s Chief Financial Officer, adopted a pre-arranged written stock sale plan in accordance with Rule 10b5-1 (the “Waters Rule 10b5-1 Plan”) under the Exchange Act, for the sale of shares of the Company’s common stock. The Waters Rule 10b5-1 Plan was entered into in accordance with the Company’s policies regarding transactions and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The Waters Rule 10b5-1 Plan provides for the potential sale of up to 59,127 shares of the Company’s common stock during various specified trading periods through June 17, 2027. | |||||
| Alaleh Nouri Chief Legal Officer |
Ended 10b5-1 plan | Jun 3, 2025 | 10-Q Aug 7, 2025 | ||
What the company wroteOn June 4, 2025, Alaleh Nouri adopted a pre-arranged written stock sale plan in accordance with Rule 10b5-1 (the “2025 Nouri Rule 10b5-1 Plan”) under the Exchange Act, for the sale of shares of the Company’s common stock and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act stock. The 2025 Nouri Rule 10b5-1 Plan was entered into during an open trading window in accordance with the Company’s policies regarding transactions. The 2025 Nouri Rule 10b5-1 Plan provides for the potential sale of up to a maximum of 70,836 shares of the Company’s common stock during various specified trading periods through September 7, 2026. | |||||
| Reza Zadno Chief Executive Officer |
Adopted 10b5-1 plan | Jun 3, 2025 | 10-Q Aug 7, 2025 | ||
What the company wroteOn June 3, 2025, Reza Zadno, the Company’s Chief Executive Officer, adopted a pre-arranged written stock sale plan in accordance with Rule 10b5-1 (the “Zadno Rule 10b5-1 Plan”) under the Exchange Act, for the sale of shares of the Company’s common stock and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act stock. The Zadno Rule 10b5-1 Plan was entered into during an open trading window in accordance with the Company’s policies regarding transactions. The Zadno Rule 10b5-1 Plan provides for the potential sale of up to 76,978 shares of the Company’s common stock during various specified trading periods through December 17, 2025. | |||||
| Antal Desai | Adopted 10b5-1 plan | Nov 21, 2024 | 10-K Feb 27, 2025 | ||
What the company wroteOn November 21, 2024, Antal Desai, a member of the Company’s Board of Directors, adopted a pre-arranged written stock sale plan in accordance with Rule 10b5-1 (the “Desai Rule 10b5-1 Plan”) under the Exchange Act, for the sale of shares of the Company’s common stock held by the 2:22 DNA Trust. The Desai Rule 10b5-1 Plan was entered into during an open trading window in accordance with the Company’s policies regarding transactions in the Company’s securities and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The Desai Rule 10b5-1 Plan provides for the potential sale of up to 150,000 shares of the Company’s common stock during various specified trading periods through June 13, 2025. | |||||
| Alaleh Nouri Chief Legal Officer |
Adopted 10b5-1 plan | Sep 3, 2024 | 10-Q Oct 28, 2024 | ||
What the company wroteOn September 3, 2024, Alaleh Nouri, the Company’s Chief Legal Officer, adopted a pre-arranged written stock sale plan in accordance with Rule 10b5-1 (the “Nouri Rule 10b5-1 Plan”) under the Exchange Act, for the sale of shares of the Company’s common stock. The Nouri Rule 10b5-1 Plan was entered into during an open trading window in accordance with the Company’s policies regarding transactions in the Company’s securities and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The Nouri Rule 10b5-1 Plan provides for the potential sale of up to 56,185 shares of the Company’s common stock during various specified trading periods through December 31, 2025. | |||||
| Reza Zadno Company’s Chief Executive Officer |
Adopted 10b5-1 plan | Aug 8, 2024 | 10-Q Oct 28, 2024 | ||
What the company wroteOn August 8, 2024, Reza Zadno, the Company’s Chief Executive Officer, adopted a pre-arranged written stock sale plan in accordance with Rule 10b5-1 (the “Zadno Rule 10b5-1 Plan”) under the Exchange Act, for the sale of shares of the Company’s common in the Company’s securities and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act stock. The Zadno Rule 10b5-1 Plan was entered into during an open trading window in accordance with the Company’s policies regarding transactions. The Zadno Rule 10b5-1 Plan provides for the potential sale of up to 105,683 shares of the Company’s common stock during various specified trading periods through December 4, 2024. | |||||
| Kevin Waters Chief Financial Officer |
Adopted 10b5-1 plan | Jun 13, 2024 | 10-Q Aug 2, 2024 | ||
| Antal Desai Company’s Board of Directors |
Adopted 10b5-1 plan | May 30, 2024 | 10-Q Aug 2, 2024 | ||
| Alaleh Nouri Chief Legal Officer |
Adopted 10b5-1 plan | Mar 13, 2024 | 10-Q/A Jun 27, 2024 | ||
| Sham Shiblaq Chief Commercial Officer |
Adopted 10b5-1 plan | Mar 9, 2024 | 10-Q/A Jun 27, 2024 | ||
| Frederic Moll M.D., the Chair of the Company’s Board of Directors |
Adopted plan | Feb 29, 2024 | 10-Q May 2, 2024 | ||
What the company wroteOn February 29, 2024, Frederic Moll, M.D., the Chair of the Company’s Board of Directors, terminated a pre-arranged written stock sale plan in accordance with Rule 10b5-1 (the “Moll 10b5-1 Plan”) under the Exchange Act, for the sale of shares of the Company’s common stock. The Moll 10b5-1 Plan was terminated during an open trading window in accordance with the Company’s policies regarding transactions in the Company’s securities and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The Moll 10b5-1 Plan provided for the potential sale of up to 237,000 shares of the Company’s common stock, so long as the market price of the Company’s common stock was higher than certain minimum threshold prices specified in the Moll 10b5-1 Plan. The Moll 10b5-1 Plan was to expire on December 31, 2024, or on such earlier date on which all of the trades thereunder had been executed. | |||||
| Frederic Moll, M.D. Chair of the Company’s Board of Directors |
Ended 10b5-1 plan | Feb 29, 2024 | 10-Q/A Jun 27, 2024 | ||
Show the other 4 plans
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 17 filings checked since May 4, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Nov 6, 2026 | Sharma Pooja Officer |
4,710 | $93K |
| Sep 9, 2026 | Nouri Alaleh Officer |
297 | $6K |
| Sep 9, 2026 | Templin Barry L Officer |
373 | $8K |
| Sep 9, 2026 | Waters Kevin Officer |
373 | $8K |
| Jun 8, 2026 | Nouri Alaleh Officer |
285 | $8K |
| Jun 8, 2026 | Waters Kevin Officer |
357 | $10K |
| Jun 8, 2026 | Templin Barry L Officer |
358 | $10K |
| Mar 19, 2026 | Alalah Nouri Officer |
5,363 | $140K |
| Mar 17, 2026 | Nouri Alaleh Officer |
304 | $9K |
| Mar 17, 2026 | Waters Kevin Officer |
706 | $20K |
| Mar 10, 2026 | Alalah Nouri Officer |
3,243 | $82K |
| Mar 6, 2026 | Nouri Alaleh Officer |
6,892 | $163K |
| Mar 6, 2026 | Waters Kevin Officer |
6,721 | $159K |
Show the other 5 notices
From the Form 144 XML filed with the SEC, since Mar 6, 2026. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PRCT/export.csv") into a cell.